NCT03704805

Brief Summary

The aim of the study is to examine the effect of a psychological intervention on antiretroviral therapy outcomes and symptoms of common mental health disorders among adults living with HIV and common mental disorders in rural Zimbabwe.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
480

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 5, 2018

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

October 10, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 15, 2018

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2020

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 5, 2021

Completed
Last Updated

May 1, 2023

Status Verified

April 1, 2023

Enrollment Period

1.8 years

First QC Date

October 10, 2018

Last Update Submit

April 27, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Average difference in mean antiretroviral therapy adherence between 2 and 6 months

    Adherence will be calculated as percentage of prescribed doses taken and measured with the Medication Event Monitoring System (MEMS)

    2-6 months

Secondary Outcomes (4)

  • Difference in mean antiretroviral therapy adherence between 1 and 12 months

    1-12 months

  • Difference in change from baseline in Shona Symptoms Questionnaire (SSQ-14) score

    At month 3, 6, 9, and 12

  • Difference in change from baseline in Patient Health Questionnaire (PHQ-9) score

    At month 3, 6, 9, and 12

  • Viral load suppression (<1000 copies per milliliter)

    At month 6 (i.e., day 180 ± 90 days) and month 12 (i.e., day 360 ± 90 days)

Study Arms (2)

Problem-Solving Therapy

EXPERIMENTAL

Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.

Behavioral: Friendship bench interventionOther: Enhanced Standard of Care

Enhanced Standard of Care

ACTIVE COMPARATOR

Participants in the control group receive enhanced standard of care.

Other: Enhanced Standard of Care

Interventions

The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.

Problem-Solving Therapy

Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.

Enhanced Standard of CareProblem-Solving Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥18 years
  • Use of first-line antiretroviral therapy for at least 6 months
  • Resident in Bikita District
  • Knowledge of English or Shona language
  • Ability to comprehend the information on the study
  • Positive screening for common mental disorders (SSQ-14 score ≥9)
  • Providing informed consent

You may not qualify if:

  • Current psychosis / cognitive impairment
  • Clinical AIDS (WHO clinical stage 4)
  • Known pregnancy or ≤3 months postpartum

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Solidarmed

Masvingo, Zimbabwe

Location

Related Publications (3)

  • Haas AD, Kunzekwenyika C, Manzero J, Hossmann S, Limacher A, van Dijk JH, Manhibi R, von Groote P, Hobbins MA, Verhey R, Egger M; Friendship Bench ART trial group. Effect of the Friendship Bench Intervention on Antiretroviral Therapy Outcomes and Mental Health Symptoms in Rural Zimbabwe: A Cluster Randomized Trial. JAMA Netw Open. 2023 Jul 3;6(7):e2323205. doi: 10.1001/jamanetworkopen.2023.23205.

  • Haas AD, Kunzekwenyika C, Manzero J, Hossmann S, Limacher A, van Dijk JH, Manhibi R, von Groote P, Hobbins MA, Verhey R, Egger M; Friendship Bench ART trial group. Effect of the Friendship Bench intervention on antiretroviral therapy outcomes and mental health symptoms in rural Zimbabwe: A cluster randomized trial. medRxiv [Preprint]. 2023 Jan 22:2023.01.21.23284784. doi: 10.1101/2023.01.21.23284784.

  • Haas AD, Kunzekwenyika C, Hossmann S, Manzero J, van Dijk J, Manhibi R, Verhey R, Limacher A, von Groote PM, Manda E, Hobbins MA, Chibanda D, Egger M; IeDEA Southern Africa. Symptoms of common mental disorders and adherence to antiretroviral therapy among adults living with HIV in rural Zimbabwe: a cross-sectional study. BMJ Open. 2021 Jul 7;11(7):e049824. doi: 10.1136/bmjopen-2021-049824.

MeSH Terms

Conditions

Mental DisordersHIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Andreas D Haas, PhD

    Institute of Social and Preventive Medicine (ISPM), University of Bern

    PRINCIPAL INVESTIGATOR
  • Cordelia Kunzekwenyika, MD

    SolidarMed, Swiss Organisation for Health in Africa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Cluster-randomized, controlled, two-arm multicenter, superiority trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 10, 2018

First Posted

October 15, 2018

Study Start

October 5, 2018

Primary Completion

July 15, 2020

Study Completion

February 5, 2021

Last Updated

May 1, 2023

Record last verified: 2023-04

Locations